1. Scrip
  3. >>Manufacturing

CordenPharma Will Scale Up To Address GLP-1 Shortage

 
• By Joseph Haas

The Swiss contractor said it will invest about $981m to increase manufacturing capacity for GLP-1 peptides in the US and EU, to fulfill API contracts worth more than $3bn.

APIs
CordenPharma is scaling up to produce more GLP-1 APIs for clients • Source: Shutterstock

CordenPharma is undertaking a major expansion of its manufacturing capabilities to meet the global need for GLP-1 agonist-containing therapies, the Basel-based firm said on 16 July. In all, the contract manufacturing and development organization plans to spend approximately €900m (about $981.4m) over the next three years to expand a manufacturing site in Colorado and build a new site in Europe as well.

In an interview, CEO Michael Quirmbach said he could not divulge which companies CordenPharma is or will be providing GLP-1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.